Anuh Pharma Limited · NSE:ANUHPHR
Anuh Pharma — FY2026 Earnings Presentation
40 slides from Anuh Pharma's earnings presentation, May 28, 2026
Slide 1: Intimation letter to stock exchanges
Date: 28th May, 2026 To, To, The Manager (Listing) Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, G Block, Dalal Street, Fort, Mumbai - 400 001 Bandra-Kurla Complex, Bandra (E), Mumbai – 400051 BSE Scrip Cod
Slide 2: Anuh Pharma Ltd. Investor Presentation FY2026
ANUH PHARMA LTD. Investor Presentation FY2026 (May-26) BSE Scrip Code: 506260 Bloomberg Code: ANUH IN Reuters Code: ANUH.BO www.anuhpharma.com 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement This presentation may include certain “forward looking statements”, based on current expectations, within the meaning of applicable laws and regulations. Actual results may differ and the Company does not guarantee realization of these statements. The Company also disclaims any
Slide 4: Table of content
Table of content 01 FY 2026 & FY 2025 HIGHLIGHTS 02 COMPANY OVERVIEW 03 INFRASTRUCTURE 04 FUTURE OUTLOOK 05 CORPORATE SOCIAL RESPONSIBILITY ANUH PHARMA LTD.
Slide 5: FY 2026 & FY 2025 Highlights
FY 2026 & FY 2025 HIGHLIGHTS
Slide 6: Message from Joint MD
Message from Joint MD Dear Shareholders, Investors and partners, On behalf of the Board of Directors, it gives me immense pleasure to present our performance report for the fourth quarter and the financial year ended March 31, 2026. This year marks an important milestone for Anuh Pharma Ltd., highli
Slide 7: Message from Joint MD
Message from Joint MD FY26 revenue increased by 15.66% to Rs. 776 Cr., supported by strong volume growth and Revenue expansion in regulated markets. Growth The company maintained healthy profitability through operational efficiencies and an improved Profitability product mix despite global market ch
Slide 8: Message from Joint MD
Message from Joint MD The path ahead: As we look forward, the fundamental drivers of Anuh Pharma Ltd. remain stronger than ever. The extensive volume expansions across our API lines, coupled with high-value regulatory market growth, have placed us in an well- positioned for sustainable long-term gro
Slide 9: Financial performance highlights (last 5 years)
Financial performance highlights (last 5 years) Total Revenue (INR in Cr.) EBITDA (INR in Cr.) 776 87 659 671 70 537 66 492 57 52 21-22 22-23 23-24 24-25 25-26 21-22 22-23 23-24 24-25 25-26 PBT (INR in Cr.) PAT (INR in Cr.) 78 60 61 54 47 47 47 39 36 31 21-22 22-23 23-24 24-25 25-26 8
Slide 10: Business mix revenue contribution
Business mix revenue contribution Revenue Split (Rs. In Cr.) Top 5 customers contribution 417 42% 355 365 297 34% 31% 31% 31% 28% Domestic Export FY 26 FY 25 FY 26 FY 25 Export Sales Domestic Sales Total Sales GEOGRAPHICAL EXPORT SALES FY 2026 GEOGRAPHICAL EXPORT SALES FY 2025 LATIN AMERICA LATIN AM
Slide 11: Product mix revenue contribution
Product mix revenue contribution FY25 FY26 (INR in Cr.) 241 221 110 110 100 102 90 82 68 58 33 34 38 42 28 21 20 27 Erythromycin Higher Chloramhenicol Pyrazinamide Sulphadoxine Cortico Ambroxol HCL Gliclazide Other Items Macrolides Steroids 10
Slide 12: Track Record
Track Record EBITDA Margin % Net Profit Margin % 13.48 9.30 10.69 10.89 10.64 6.86 7.16 6.28 8.56 5.32 21-22 22-23 23-24 24-25 25-26 21-22 22-23 23-24 24-25 25-26 ROE (%) ROCE (%) 22.50 26.82 18.58 19.85 18.85 15.11 15.90 15.34 15.89 12.10 21-22 22-23 23-24 24-25 25-26 21-22 22-23 23-24 24-25 25-26
Slide 13: Track Record
Track Record Outflow of Dividend (INR in Cr.) Current ratio 15 15 2.20 2.22 13 2.11 10 9 1.98 1.91 21-22 22-23 23-24 24-25 25-26 # 21-22 22-23 23-24 24-25 25-26 # Recommended by BOD, subject to members' approval Debt to Equity Cash Conversion Cycle (Days) 86 0.03 72 58 56 61 0.01 0.01 - - 21-22 22-2
Slide 14: FY 26 and FY 25 Financial Performance
FY 26 and FY 25 Financial Performance Rs. In Crores 3 months 3 months 12 months 12 months % Change % Change Financial Highlights ended ended ended ended QOQ YoY 31/03/2026 31/12/2025 31/03/2026 31/03/2025 Operating Revenue 202.12 197.18 2.50 771.66 661.51 16.65 Operating Profit 44.44 38.91 14.20 145
Slide 15: Company Overview
a | ak 7 my — Lah } | COMPANY | a. OVERVIEW eee
Slide 16: Company Overview
Company Overview The Company derived ~46% of its revenues from exports in FY26. The Company has strong marketing partnerships with 360 customers in over 72 countries including Europe, Mexico and South Africa. The expansion project with state of the art manufacturing facility targeted at regulated ma
Slide 17: Journey So Far…
Journey So Far… Year Achievements 1989 Started manufacturing Erythromycin salts with capacity of 150 MTPA , followed by doubling the capacity to 300 MTPA in 1995. 2002 Received WHO-GMP for its facilities. 2006 Doubled the capacity by acquiring new plot of 1800 SQMT to expand the output capacity 600
Slide 18: Journey So Far…
Journey So Far… Year Achievements 2020 Received approval from WHO Geneva prequalification for Pyrimethamine API 2023 Received CEP from EDQM for Sulphadoxine. 2023 Received CEP from EDQM for Azithromycin (Higher macrolides) 2023 Received CEP from EDQM for Gliclazide (Anti Diabetic) 2023 Enhanced the
Slide 19: Competitive Advantage
Competitive Advantage Market leadership: Erythromycin salts Competitive Advantage Pyrazinamide • Regulatory approvals • Environmental health and Safety Compliance (Audited an Sulfadoxine approved by Multinational companies). Ambroxol HCL • Well diversified sourcing with backward integration in key p
Slide 20: Product List
Product List Macrolides Higher Macrolides Anti Asthamatics Anti Histamine 1. Erythromycin 11,12 Carbonate 1. Azithromycin 1. Acebrophylline Bilsatin 2. Erythromycin Base 3. Erythromycin Estolate 4. Erythromycin Propionate 5. Erythromycin Ethyl Succinate 6. Erythromycin Phosphate 7. Erythromycin Stea
Slide 21: Product List
Product List Corticosteroids 1. Beclomethasone Dipropionate 11. Prednisolone Acetate 2. Betamethasone Acetate 12. Prednisolone Sodium Phosphate 3. Betamethasone Dipropionate 13. Triamcinolone Acetonide 4. Betamethasone Sodium Phosphate 14. Triamcinolone Base 5. Betamethasone Valerate 15. Methyl Pred
Slide 22: Key Management Personnel & Senior Management
Key Management Personnel & Senior Management VC VICE CHAIRMAN MR. BIPIN SHAH JMD JMD JOINT JOINT MANAGING MANAGING DIRECTOR DIRECTOR MR. RITESH SHAH MR. VIVEK SHAH CMO COMPLIANCE CMO CS & VP EM CFO OFFICER MM R&D QUALITY OPERATION QUALITY MR. RAJU MR. DARSHAN MR. MANAN MR. VINAYAK DR. SANJAY MR. SAN
Slide 23: Key Management Personnel & Senior Management
Key Management Personnel & Senior Management Name Designation Profile Mr. Arun Todarwal Chairman Fellow member of the ICAI and having practice since 1981. He has handled various professional assignments in India and abroad including Audits, Taxation, International Taxation, Joint Ventures, Due Dilig
Slide 24: Latest Shareholding Pattern
Latest Shareholding Pattern Public 28.18 % Promoter & Promoter Group, 71.82 % Market capitalization INR 763 Cr. (As on 22nd May, 2026) Free float market capitalization INR 215 Cr. (As on 22nd May, 2026) 23
Slide 25: Infrastructure
INFRASTRUCTURE
Slide 26: State of Art manufacturing facility
State of Art manufacturing facility • Anuh Pharma has a EUGMP/ WHO Pre qualified approved manufacturing facility at Tarapur spread across 11,400 sq. meters with 9 API’s blocks and 2 intermediate block with total capacity of 2400 MTPA – this includes new expanded capacity. • With commissioning of Zer
Slide 27: Manufacturing facility Photos
Manufacturing facility Photos
Slide 28: Manufacturing facility Photos
Manufacturing facility Photos
Slide 29: Manufacturing facility Photos
Manufacturing facility Photos
Slide 30: Manufacturing facility Photos
Manufacturing facility Photos
Slide 31: Manufacturing facility Photos
Manufacturing facility Photos
Slide 32: Other Facilitates
Other Facilitates The entire facility is equipped with latest Fire Fighting and Safety Measures. Zero Liquid Discharge Effluent Control system for treating 100% of Generated Pollution. 100% Power Backup via dedicated power line from Power Distributor to our premises. Adjoining office and a Training
Slide 33: Dedicated Research & Development Facility
Dedicated Research & Development Facility FACILITATE ACTIVITIES LAB SCALE REACTION THAT LEAD TO DEVELOP PROCESSES AND BATCHES TO VALIDATE CHARACTERIZATION AND PRODUCTS. RESEARCH PROFILING OF PRODUCTS. ANALYTICAL DEV CHEMICAL SYNTHESIS PILOT PLANT IN HOUSE R&D LAB APL NEW PRODUCTS & PROCESSES A dedic
Slide 34: Future Outlook
FUTURE OUTLOOK
Slide 35: Future Outlook – Growth Strategy
Future Outlook – Growth Strategy As we look forward, the fundamental drivers of Anuh Pharma Ltd. remain stronger than ever. The extensive volume expansions across our API lines, coupled with high-value regulatory market growth, have placed us in an well-positioned for sustainable long-term growth. W
Slide 36: Future Outlook – Product under development
Future Outlook – Product under development Sr. No Product Name Therapeutic application 1) Vonoprazon Anti-Ulcerative Fumarate 2) Pretomanid Anti TB 3) Edoxaban Tosylate Anti-coagulant 35
Slide 37: Corporate Social Responsibility
CORPORATE SOCIAL RESPONSIBILITY
Slide 38: CSR …. Servicing Society for better tomorrow
CSR …. Servicing Society for better tomorrow Donated to Chhatrapati Shikshan Mandal for Building of Toilet Block for about 3200 student of the School Donated to Churchgate Lions Service Funds for Donated to Indian Development Promoting Sports for Foundation (Project Aashayein) for specially challeng
Slide 39: CSR …. Servicing Society for better tomorrow
CSR …. Servicing Society for better tomorrow Donated to Late Shri Kantilal Manilal sonawala Charitable Trust for providing education and accommodation to the needy girls Donated to Indian Development Foundation (Project Dignity) for providing menstrual hygiene kits and sanitary pads for the needy gi
Slide 40: Thank You
Thank You For specific queries please feel free to contact; Mr. Darshan Rampariya (CFO) darshan.r@anuhpharma.com